Indications:

Kinlytic is indicated in adults for the lysis of acute massive pulmonary emboli, defined as obstruction of blood flow to a lobe or multiple segments and for the lysis of pulmonary emboli accompanied by unstable hemodynamics, ie, failure to maintain blood pressure without supportive measures. The diagnosis should be confirmed by objective means, such as pulmonary angiography or noninvasive procedures such as lung scanning.

Important Safety Information:

The use of Kinlytic (urokinase for injection) is contraindicated in patients with a history of hypersensitivity to the product. Because thrombolytic therapy increases the risk of bleeding, Kinlytic is contraindicated in the following situations: active internal bleeding; recent (eg, within two months) cerebrovascular accident; recent (eg, within two months) intracranial or intraspinal surgery; recent trauma including cardiopulmonary resuscitation; intracranial neoplasm, arteriovenous malformation, or aneurysm; known bleeding diatheses; or severe uncontrolled arterial hypertension.

The risk of serious bleeding is increased with use of Kinlytic. In the following conditions, the risk of bleeding may be increased and should be weighed against the anticipated benefits: recent (within 10 days) major surgery, obstetrical delivery, organ biopsy, previous puncture of non-compressible vessels; recent (within 10 days) serious gastrointestinal bleeding; pregnancy; cerebrovascular disease; diabetic hemorrhagic retinopathy; or any other condition in which bleeding might constitute a significant hazard or be particularly difficult to manage because of its location.